Photodynamic therapy (PDT), a promising new therapeutic modality for the management of a variety of solid malignancies and many non-malignant diseases, is a bimodal therapy using a porphyrin based photosensitizing chemical and visible light. The proper understanding of the mechanism of PDT-mediated cancer cell-kill may result in improving the ecacy of this treatment modality. Earlier we have shown (Proc. Natl. Acad. Sci. USA; 95: 6977-6982, 1998) that silicon phthalocyanine (Pc4)-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21 which, by inhibiting cyclins (E and D1) and cyclin dependent kinases (cdk2 and cdk6), results in a G0/G1-phase arrest followed by apoptosis in human epidermoid carcinoma cells A431. We have also demonstrated the generation of nitric oxide during PDT-mediated apoptosis (Cancer Res.; 58: 1785-1788. Retinoblastoma (pRb) and E2F family transcription factors are important proteins, which regulate the G1?S transition in the cell cycle. Here, we provide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis. Western blot analysis demonstrated a decrease in the hyper-phosphorylated form of pRb at 3, 6 and 12 h post-PDT with a relative increase in hypo-phosphorylated pRb. Western blot analysis also revealed that PDT-caused decrease in phosphorylation of pRb occurs at serine-780. The ELISA data demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT. This response was accompanied with down-regulation in the protein expression of all ®ve E2F (1 ± 5) family transcription factors, and their heterodimeric partners DP1 and DP2. These results suggest that Pc4-PDT of A431 cells results in a down regulation of hyper-phosphorylated pRb protein with a relative increase in hypo-phosphorylated pRb that, in turn, compromises with the availability of free E2F. We suggest that these events result in a stoppage of the cell cycle progression at G1?S transition thereby leading to a G0/G1 phase arrest and a subsequent apoptotic cell death. These data provide an evidence for the involvement of pRb-E2F/DP machinery in PDTmediated cell cycle arrest leading to apoptosis.
Introduction
Photochemotherapy of cancer, popularly known as photodynamic therapy (PDT), is a promising new therapeutic procedure that relies on a bimodal protocol comprised of chemical-photosensitization and lightirradiation. These two components, individually, are non toxic but tumoricidal in combination. The treatment is based on a selective uptake of porphyrinbased photosensitizing chemical in tumor tissue relative to the surrounding normal tissue followed by irradiation of the tumor with light (visible or near infra-red), typically delivered through a laser. PDT is showing promise against a variety of solid tumors as well as against many non-malignant diseases (Dougherty et al., 1998; Pass, 1993; Tom, 1997; Gomer, 1991) . PDT is known to result in a sequence of photochemical and photobiological events that leads to an oxidative damage to many of cellular targets, subsequently resulting in the killing of cancerous cells and thereby tumor ablation that often leads to a complete cure (Dougherty et al., 1998) . The mechanism(s) of the PDT-mediated cell killing that results in tumor ablation is not fully understood. However, the involvement of apoptosis has been established as an early event, both in vitro and in vivo situations (Agarwal et al., 1991; Zaidi et al., 1993; Luo et al., 1996) . It is generally believed that the apoptotic response of PDT is critical for its therapeutic ecacy. Complete understanding of the mechanism(s) by which PDT causes tumor ablation may improve its therapeutic ecacy.
Research aimed at de®ning the mechanism(s) of biological eects of PDT has demonstrated the involvement of singlet oxygen and possibly other reactive oxygen species as a pre-requisite for PDTeect (Dougherty et al., 1998) . Studies have also suggested the involvement of certain early response genes such as c-fos, c-jun, c-myc, egr-1 (Luna et al., 1994) , heat shock protein HSP-70 (Gomer et al., 1996) and nuclear factor kappa B (NFkB) as PDT-response (Ryter and Gomer, 1993) . The stimulation of stressactivated protein kinase (SAPK) and p38 high osmolarity glycerol protein (p38 HOG1) kinase in murine keratinocytes following PDT with benzoporphyrin derivative has been shown (Tao et al., 1996) . Reports have indicated the involvement of phospholipases A 2 and C, and intracellular Ca 2+ in PDTmediated apoptosis (Agarwal et al., 1993) . Recent studies have implicated the involvement of ceramide (Separovic et al., 1997) and caspases (Granville et al., 1997; He et al., 1998) during PDT-mediated apoptosis.
Well established is the fact that the progression through the cell cycle is governed by a dynamic interaction between cyclins and cyclin dependent kinases (cdk) (Sherr, 1993; Morgan, 1995) . A variety of tumor suppressor genes such as p53, the cyclin kinase inhibitors (cki) and pRb are known to play important roles in regulating the cell cycle progression Gartenhaus et al., 1996; Hsu et al., 1997 , Goldberg et al., 1996 Kasten and Giordano, 1998) . Retinoblastoma (pRb) is a phosphoprotein that controls the progression of cell cycle in late G1-phase (Kasten and Giordano, 1998; Linke et al., 1997; and references therein) . Several lines of evidence support the hypothesis that pRb may inhibit apoptosis (Kasten and Giordano, 1998; and references therein) . pRb acts to connect the cell cycle to the transcriptional machinery by binding to and inhibiting the activity of the E2F family of transcription factors (Weinberg, 1995 (Weinberg, , 1996 Taya, 1997) .`E2F family of transcription factors' subsumes a group of ®ve related proteins (E2F1 through E2F5). The activity of E2F depends on the heterodimerization with a protein belonging to DP family (Lam and La Thangue, 1994; Muller, 1995) . The ability of pRb to bind E2F and regulate cell cycle depends on its phosphorylation status. When under (hypo)-phosphorylated, pRb is capable of associating with E2F and this binding prevents E2F from activating its target genes that results in a repressed transcription (Lam and Watson, 1993; Weintraub et al., 1995) . Phosphorylation of pRb (that may be caused by cyclin-cdk complexes) results in the release of`free' E2F and thereby activation of genes required for DNA synthesis (Taya, 1997) . Without this phorphorylating event, pRb prevents the further advancement of cell cycle progression at G1?S transition, which results in a G1 cell cycle arrest (Kasten and Giordano, 1998) .
In a recent study, we demonstrated that PDT results in an induction of the cyclin kinase inhibitor WAF1/ CIP1/p21, which through downregulating cyclins (E and D1)/cyclin dependent kinases (cdk2 and cdk6) results in a G0/G1-phase arrest of the cell cycle in human epidermoid carcinoma cells A431 . Based on these data, we suggested that PDTinduced cell cycle arrest is an irreversible process that ultimately leads to apoptotic cell death. In another study from this laboratory, we have shown the generation of nitric oxide during PDT-mediated apoptosis (Gupta et al., 1998) . Here, we provide evidence for the involvement of pRb-E2F/DP machinery as an important contributor of PDT-mediated cell cycle arrest and apoptosis.
Results and discussion
The major challenge for an eective cancer therapeutic regimen is to selectively kill the malignant cells while sparing the normal cells. PDT is the treatment modality that seems to have a potential to meet this challenge. A vast majority of pre-clinical and clinical studies conducted worldwide in last 25 years have established that PDT is a promising therapeutic procedure for the management of a variety of solid tumors (Tom, 1997; Dougherty et al., 1998) . The USFDA approved PDT (with Photofrin 1 as a photosensitizer) as a therapeutic modality in the year 1995 for treating selected patients with advanced esophageal cancer (Dougherty et al., 1998) . More recently, in January 1998, the use of PDT for the treatment of micro-invasive lung cancer was also approved by the USFDA (Dougherty et al., 1998) . Currently, in a number of investigator-or institutioninitiated clinical trials worldwide, PDT is being investigated as a modality for the treatment of a variety of cancer types. Photofrin 1 a mixture of porphyrins, is shown to be an eective photosensitizer for PDT for humans. Photofrin 1 has some undesirable features such as (i) it is a complex mixture; (ii) it utilizes 625 ± 630 nm wavelength range of its absorption spectrum for the treatment protocol that has limited penetration in the tissue; and (iii) it causes severe and persistent cutaneous photosensitivity. The model photosensitizer with which we have been working is a silicon phthalocyanine compound [HOSiPcOSi(CH 3 ) 2 (CH 2 ) 3 N(CH 3 ) 2 ] termed as`Pc4' that was developed at this institution . Based upon encouraging experimental results (Agarwal, 1996; Separovic et al., 1997; BenHur et al., 1997; Ahmad et al., 1998) and precilinical pharmacokinetics, ecacy and toxicology studies completed by the`Drug Decision Network' of the National Cancer Institute, Pc4 has been recommended for clinical testing.
The molecular events which lead to tumor-destruction following PDT are not well understood. De®ning these events may be helpful in improving PDT protocols for its wider application as a cancer therapeutic modality. Our recent study employing human epidermoid carcinoma cells A431, demonstrated that Pc4-PDT results in an induction of the cyclin kinase inhibitor WAF1/CIP1/p21, which through the inhibition of cyclin D1 and cyclin E, and their regulatory subunits cdk2 and cdk6, results in an imposition of arti®cial checkpoint at G1?S transition thereby resulting in an arrest of cells in G0 ± G1 phase of the cell . We suggested that this arrest is an irreversible process and the cells, unable to repair the damages, ultimately undergo apoptosis.
The phosphoprotein pRb and E2F family transcription factors are important proteins, which regulate the G1?S transition in the cell cycle (Kasten and Giordano, 1998) . Here, extending our earlier study , we performed additional experiments to evaluate the role of pRb-E2F/DP machinery during Pc4-PDT-mediated cell cycle arrest that ultimately leads to an apoptotic cell death. In the present study, for the sake of consistency and in order to correlate our ®ndings to give a composite scenario of the events involved in cell cycle-mediated apoptosis by PDT, we employed similar conditions as described earlier . Therefore, as described under Materials and methods, the cells were subjected to Pc4-PDT and harvested at 3, 6 and 12 h post-PDT. Two untreated controls (0 h and 12 h post-PDT) were employed. The 12 h untreated control was employed because it was the longest time point post-PDT in our experimental protocol. This is important to emphasize here that under the conditions employed here, the population of: (i) dead cells was 11, 21 and 52% and data not shown); (ii) cells in G0 ± G1 phase of the cell cycle was 47, 51 and 69% ; and (iii) apoptotic cells was 11, 20 and 89% , respectively at 3, 6 and 12 h post-PDT. Since there was no Photodynamic therapy causes alteration in pRb-E2F/DP machinery N Ahmad et al eect of light-or photosensitizer-alone, on cell cycle distribution and these treatments also did not induce apoptotic response, we did not include them in our detailed study. Studies have established that pRb is capable of exerting growth suppressive activity because of its interaction with E2F/DP transcription factors, which function to trigger the transcription of genes required for cell cycle progression (Muller, 1995; Taya, 1997) . Since the phosphorylation of pRb is an important event for the progression of cell cycle at G1?S transition (Lam and Watson, 1993; Weintraub et al., 1995) in the present study, we investigated the protein level and the phosphorylation pattern of pRb during Pc4-PDT-mediated cell cycle arrest and apoptosis. The Western blot analysis (Figure 1 ) demonstrated a decrease in the level of pRb at 3, 6 and 12 h post-PDT as compared to the controls. pRb modulation of G1?S transition is controlled, partly if not totally, by cell-cycle dependent phosphorylation (Linke et al., 1997; and references therein) . pRb is largely found in hypophosphorylated form in early G1 phase (Hiebert et al., 1992) . The hypo-phosphorylated pRb is able to bind to a subset of E2F/DP heterodimers, thereby inhibiting their transcriptional activation potential (Hiebert et al., 1992) . pRb is known to be phosphorylated twice during the cell cycle (i) in mid G1 to late G1 phase when the cells reach the restriction point, speci®cally by cyclin D/cdk6 complex; and (ii) further near G1?S transition, by cyclin A/cdk2 and cyclin E/cdk2 complexes (Linke et al., 1997 ; and references therein). Since we have earlier shown that PDT results in an inhibition of cyclin D1/cdk6 as well as cyclin E/cdk2, it is reasonable to suggest that the phosphorylation of pRb is possibly inhibited by PDT at both the occasions discussed above i.e. ®rst in mid to late G1 by cyclin D1/ cdk6 and then at G1?S transition by cyclin E/ cdk2. It is important to emphasize here that due to PDT the decrease in hyper-phosphorylated pRb (upper band; slower migration) was much more pronounced than the decrease in hypo-phosphorylated pRb (lower band; faster migration). Therefore, the data indicate that PDT caused a relative increase in hypo-phosphorylated pRb. This kind of response has been reported earlier where Goldberg et al. (1996) demonstrated that the non-steroidal anti-in¯ammatory drugs viz. sulindac and sulindac sul®de results in a reduction in the levels of pRb with a relative increase in the amount of hypophosphorylated pRb in human colon adenocarcinoma cell line HT-29. To further con®rm that the PDT results in a decrease in the phosphorylation of pRb, we conducted Western blot analysis using a phospho-speci®c antibody (rabbit-polyclonal) raised against a synthetic human phospho-Rb (Ser780) peptide (TRPPTLS(p)PIPHIP-KLH). This antibody speci®cally recognizes the pRb protein that is phosphorylated at serine-780, and it does not cross react with non-phosphorylated forms of pRb as the reactivity with non-phospho-Rb had been removed by anity chromatography (MBL Laboratories Co. Ltd., Naka-ku Nagoya, Japan). As shown in Figure 2a , the Western blot analysis clearly revealed that PDT results in a decrease in Figure 1 Eect of Pc4-PDT on protein expression of pRb. The cells were subjected to PDT and harvested at 3, 6 and 12 h post-PDT. Total cell lysates were prepared and 50 mg protein was subjected to SDS ± PAGE followed by Western blot analysis using appropriate primary antibody and secondary HRP conjugates. The proteins were detected by chemiluminiscence. The upper band (slower migration) represents the hyper-phosphorylated form (ppRb), and the lower band (faster migration) represents hypo-phosphorylated form (pRb). The details are described under Materials and methods. Equal loading was con®rmed by stripping the membrane and re-probing it with b-actin primary antibody and appropriate secondary HRP conjugate. Data from a typical experiment repeated three times with similar result is shown a b Figure 2 (a) Eect of Pc4-PDT on serine phosphorylation of pRb. The cells were subjected to PDT and harvested at 3, 6 and 12 h post-PDT. Total cell lysates were prepared and 50 mg protein was subjected to SDS ± PAGE followed by Western blot analysis using a phospho-speci®c antibody (rabbit-polyclonal) and anti rabbit secondary HRP conjugate. The proteins were detected by chemiluminiscence. Equal loading was con®rmed by stripping the membrane and reprobing it with b-actin primary antibody and appropriate secondary HRP conjugate. (b) Eect of Pc4-PDT on phosphorylation of pRb. Following PDT the cells were harvested at desired times and the amount of hypo-phosphorylated form of pRb was detected by a kit obtained from Oncogene Research Products (Cambridge, MA, USA) according to the manufacturer's protocol. The details are described under Materials and methods. Data from a typical experiment repeated three times with similar result is shown Photodynamic therapy causes alteration in pRb-E2F/DP machinery N Ahmad et al phosphorylation of pRb at serine-780. To con®rm our Western blot data (Figure 1) showing a relative increase in hypo-phosphorylated pRb, we employed ELISA using a kit (Oncogene Research Products, Cambridge, MA, USA) that quantitatively measures hypo-phosphorylated pRb. The data shown in Figure 2b , demonstrated a time dependent accumulation of hypo-phosphorylated pRb by PDT. Several lines of evidence have supported the hypothesis that Rb acts as a negative regulator of apoptosis (Kasten and Giordano, 1998) . Also, it has also been demonstrated that the predominance of hypo-phosphorylated pRb may be associated with the induction of WAF1/CIP1/p21 (Bowen et al., 1998) . Our earlier studies have shown a signi®cant induction of WAF1/CIP1/p21 by PDT. It is therefore possible that PDT-mediated accumulation of hypo-phosphorylated pRb, at least in part, is responsible for the induction of WAF1/CIP1/p21 by PDT that ultimately results in a cell cycle-mediated apoptosis. However, detailed studies are needed to strengthen this suggestion.
Since pRb connects the cell cycle to the transcriptional machinery by binding to and inhibiting the E2F transcription factors (Weinberg, 1995 (Weinberg, , 1996 Taya, 1997) , we conducted Western blot analysis to investigate to study the eect of PDT on the protein expression of E2F (1 ± 5) transcription factors. As shown in Figure 3 , PDT results in a decrease in the protein expression of all the ®ve E2F transcription factors evaluated in this study. In fact, the release of free E2F following the phosphorylation of pRb is known to activate the genes, which are responsible for an S-phase entry (Taya, 1997) . The overexpression of E2F1 itself in the primary cells, for example, results in premature S-phase entry of the cells and is sucient to overcome the G1 arrest induced by g-irradiation Figure 3 Eect of Pc4-PDT on protein expression of E2F family transcription factors. The cells were subjected to PDT and harvested at 3, 6 and 12 h post-PDT. Total cell lysates were prepared and 50 mg protein was subjected to SDS ± PAGE followed by Western blot analysis using appropriate primary antibody and secondary HRP conjugates. The proteins were detected by chemiluminiscence. The details are described under Materials and methods. Equal loading was con®rmed by stripping the membrane and re-probing it with b-actin primary antibody and appropriate secondary HRP conjugate. Data from a typical experiment repeated three times with similar result is shown Figure 4 Eect of Pc4-PDT on protein expression of DP1 and DP2. The cells were subjected to PDT and harvested at 3, 6 and 12 h post-PDT. Total cell lysates were prepared and 50 mg protein was subjected to SDS ± PAGE followed by Western blot analysis using appropriate primary antibody and secondary HRP conjugates. The proteins were detected by chemiluminiscence. The details are described under Materials and methods. Equal loading was con®rmed by stripping the membrane and re-probing it with b-actin primary antibody and appropriate secondary HRP conjugate. Data from a typical experiment repeated three times with similar result is shown Photodynamic therapy causes alteration in pRb-E2F/DP machinery N Ahmad et al (DeGregori et al., 1995) . In this study, we demonstrated a universal inhibition of E2F transcription factors by PDT. This implies a decreased availability of these transcription factors, which are important regulator of cell cycle progression at G1?S transition that results in a G1 arrest. Further, since the activity of E2F is known to depend on its heterodimeric association with a DP family member (Lam and La Thangue, 1994; Muller, 1995) , we also evaluated the eect of PDT on both members of DP protein family i.e. DP1 and DP2. The Western blot analysis data shown in Figure 4 revealed that the PDT results in a signi®cant decrease in the protein expression of DP1 as well as DP2. Employing transgenic Drosophila capable of inducible, ectopic production of E2F activity Durino et al. (1996) have demonstrated that simultaneous overexpression of dE2F and dDP induces DNA replication and target gene expression. Signi®cant decrease of both DP protein types by PDT may be an additional possibility for a dysregulation of cell cycle at G1?S transition. Taken together, our data demonstrate the involvement of pRb-E2F/DP machinery in PDT-mediated cell cycle arrest leading to apoptosis. In Figure 5 , we have attempted to piece together the information from this study and our earlier studies in this direction, to provide a composite scheme for the mechanism of PDT-mediated cell cycle arrest and apoptosis. It is important to mention here: (i) our earlier study showing an early involvement of nitric oxide (NO) during PDT-response (Gupta et al., 1998); and (ii) studies showing a possible association of NO with WAF1/CIP1/p21 (Ho et al., 1996; Ishida et al., 1997) . Therefore, in this ®gure we have suggested the involvement of NO as an upstream event during PDT-response. However, a detailed study to investigate the involvement of NO in PDT-mediated WAF1/CIP1/p21 induction is one of our future goals.
Materials and methods

Cells and photodynamic therapy
The human epidermoid carcinoma cells A431 were obtained from American Type Culture Collection, (Rockville, MD, USA) and maintained in Dulbecco's Modi®ed Eagle Medium (DMEM) supplemented with 10% fetal bovine serum, 1% penicillin/streptomycin, under standard culture conditions. In all the experiments, 70 ± 80% con¯uent cells were used.
The phthalocyanine photosensitizer Pc4 was provided by Drs Ying syi Li and Malcolm E Kenney of the Department of Chemistry at Case Western Reserve University. Pc4 (0.5 mM) in DMF was added to the cells (in complete DMEM media in a 100620 mm Falcon disposable cell culture dish), which were incubated overnight (16 h) in a humidi®ed incubator at 378C. Next morning, the cells were washed with HBSS (with Ca 2+ and Mg
2+
), irradiated (in HBSS with Ca 2+ and Mg 2+ ) with 15 kJ/m 2 of light, as measured by a digital photometer (Tektronix, Beaverton, OR, USA), using a 300 W halogen lamp. The light delivered was ®ltered through a Lee primary red ®lter #106 (Vincent Lighting, Cleveland, OH, USA) to remove light with wavelengths of 5600 nm. The cells were then incubated in dark for selected time point in a humidi®ed incubator at 378C. After 3, 6 and 12 h following PDT the medium was aspirated, the cells were washed with cold PBS (10 mM, pH 7.4) and processed as desired. In this study, in addition to 0 h untreated control, we also included 12 h untreated control because it was the longest cell-harvesting time following PDT in our experimental protocol.
Preparation of cell lysates and Western blot analysis
Following PDT, the cells were harvested at 3, 6 and 12 h post-treatment and then washed with cold PBS (10 mM, pH 7.4). The lysis buer (50 mM Tris-HCl, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 20 mM NaF, 100 mM Na 3 VO 4 , 0.5% NP-40, 1% Triton X-100, 1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin; pH 7.4) was added to the plates which were left over ice for 30 min. The cells were scraped, the lysate was collected in a microfuge tube and passed through a 21 1/2 G needle to break up the cell aggregates. The lysate was cleared by centrifugation at 14 000 g for 15 min at 48C and the supernatant (total cell lysate) was collected, aliquoted in small portions and stored at 7708C. The protein content in the lysates was measured by DC BioRad assay as per the manufacturer's protocol (BioRad Laboratories, Hercules, CA, USA).
For Western blot analysis, 50 mg protein was resolved over 8 ± 12% polyacrylamide-SDS gels and transferred onto a nitrocellulose membrane. The non-speci®c sites were blocked by incubating the blot with 5% non-fat dry milk in buer (containing 10 mM Tris, 100 mM NaCl, 0.1% T-20) for 1 h at room temperature or overnight at 48C. The blot was washed with wash buer (10 mM Tris, 100 mM NaCl, 0.1% T-20) for 2610 min and then incubated overnight with appropriate primary antibody speci®c for the protein to be assessed. The primary antibodies used in this study were obtained from Santa Cruz Biotechnology, Inc., (Santa Cruz, CA, USA) (for pRb, E2F1, E2F5 and DP2); MBL, Ltd., (Naka-ku Nagoya, Japan) (for Ser780-phospho-Rb); and Lab Vision Corp., (Fremont, CA, USA) (for E2F2, E2F3, E2F4 and DP1) The antibodies were used at dilutions speci®ed by the manufacturer. The blot was washed for 2610 min and then incubated with the corresponding secondary antibody HRP conjugate 
pRb ELISA assay
We performed pRb-ELISA assay using a kit obtained from Oncogene Research Products (Cambridge, MA, USA).
This assay measures the amount of hypo-phosphorylated form of pRb. For pRb-ELISA assay, the A431 cells were subjected to Pc 4-PDT, harvested at desired times after PDT, the cell lysates were prepared and the assay was performed according to the manufacturer's protocol.
